Please login to the form below

Not currently logged in
Email:
Password:

mepolizumab

This page shows the latest mepolizumab news and features for those working in and with pharma, biotech and healthcare.

Novartis strengthens case for its combination asthma drug

Novartis strengthens case for its combination asthma drug

However, it was still able to establish its next-generation of respiratory products – this includes Trelegy (vilanterol/umeclidinium/ fluticasone furoate), which brought in £139 in  Q3 and Nucala (mepolizumab), which brought

Latest news

More from news
Approximately 9 fully matching, plus 50 partially matching documents found.

Latest Intelligence

  • GSK forges ahead with its dynamic COPD and asthma portfolio GSK forges ahead with its dynamic COPD and asthma portfolio

    mepolizumab to treat COPD exacerbations with eosinophilic inflammation. ... You would imagine coronavirus would be one of those threats.”. GSK is trialling its biologic anti IL-5 drug mepolizumab, licensed for severe asthma, in eosinophilic COPD with a

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
11 London

11 London is a strategic and creative agency working in the fields of health and humanity – complex areas, but...

Latest intelligence

Covid-19 redefines rules of customer engagement
Oli Hudson, Content Director at Wilmington Healthcare, explores how the pandemic has changed pharma’s relationship with HCPs...
Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians....
The concordance conundrum: understanding the complexities of behaviour change
Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....

Infographics